Krystal Biotech Hits New 52-Week High at $320.15, Up 76.67%

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 320.15 on June 10, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 76.67%, significantly outpacing the S&P 500's growth of 20.34% during the same period. The company's market capitalization stands at USD 7,173 million, reflecting its position within the small-cap segment. Krystal Biotech's price-to-earnings (P/E) ratio is currently at 35.00, indicating investor confidence in its earnings potential. Additionally, the company maintains a return on equity of 16.80%, showcasing effective management of shareholder equity. Despite the absence of dividends, Krystal Biotech's financial metrics, including a debt-to-equity ratio of -0.68 and a price-to-book ratio of 5.88, suggest a solid financial foundation. The stock's previous 52-week low was recorded at USD 127.99, highlighting the significant upward trajectory it has experienced.